Table 2.
Polymorphism patterns detected by genotype MTBDRsl assay in drug‑resistant Mycobacterium tuberculosis strains
| Second-line drugs | Genes | MTBDRs probe | Clinical implications | ||
|---|---|---|---|---|---|
| Fluoroquinolones resistance | gyrA gene | MUT 3A | 2 (12) |
Levofloxacin is not effective Moxifloxacin could be used at higher dose |
|
| MUT3B | 2 (12) |
Levofloxacin is not effective Moxifloxacin is not effective |
|||
| MUT 3C | 1 (6) | ||||
| MUT3D | 1 (6) | ||||
| MUT3B and MUT3C | 4(23) | ||||
| gyrA WT3, MUT3A, MUT3B, MUT3C, MUT3D not developed | 8 (41) |
Levofloxacin is not effective Moxifloxacin could be used at higher dose |
|||
| Total | N = 17(100%) | ||||
| Second-line injectable drugs resistance | rrs gene | MUT 1 | 1 (12) | Amikacin, kanamycin and capreomycin are not effective | |
| rrs WT1 and MUT1 not developed | 1 (12) | Kanamycin and capreomycin are likely not effective | |||
| MUT 2 | 1 (12) | Amikacin, kanamycin and capreomycin are not effective | |||
| rrs WT2 and MUT2 not developed | 6 (64) | Kanamycin and capreomycin are likely not effective | |||
| Total | N = 8(100%) | ||||